External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy

IMPORTANCE: Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined. OBJECTIVE: To assess whether the progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Satya, Chauhan, Aman, Du, Liping, Thomas, Katharine E., Jacob, Aasems, Schad, Aimee, Jain, Shikha, Jessop, Aaron, Shah, Chirayu, Eisner, David, Cardin, Dana B., Ciombor, Kristen K., Goff, Laura W., Bradshaw, Marques, Delbeke, Dominique, Sandler, Martin, Ramirez, Robert A., Berlin, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771294/
https://www.ncbi.nlm.nih.gov/pubmed/35044469
http://dx.doi.org/10.1001/jamanetworkopen.2021.44170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771294/
https://www.ncbi.nlm.nih.gov/pubmed/35044469
http://dx.doi.org/10.1001/jamanetworkopen.2021.44170

Ejemplares similares